Prevalence of Genital Human Papillomavirus Infection and Human Papillomavirus Vaccination Rates Among US Adult Men: National Health and Nutrition Examination Survey (NHANES) 2013-2014.

Abstract:

Importance:Human papillomavirus (HPV) is a common sexually transmitted infection that is a major cause of noncervical anogenital and oropharyngeal cancers. Prophylactic HPV vaccine is available for primary prevention. However, the population prevalence data for male genital HPV infection is not well known, while the HPV vaccination coverage is low in the United States. Objectives:To estimate the prevalence of genital HPV infection and the HPV vaccination rate in the United States among adult men and to examine potential risk factors for HPV infection. Design, Setting, and Participants:The National Health and Nutrition Examination Survey (NHANES) samples a representative cross-section of the US population. Men aged 18 to 59 years were examined in mobile examination centers during the NHANES 2013-2014. DNA was extracted from self-collected penile swab specimens, and HPV genotyping was performed by polymerase chain reaction amplification. Demographic and vaccination information was gathered via self-report during home-based standardized interviews. Binary multivariable logistic regression was used to estimate the odds of HPV infection. Main Outcomes and Measures:The prevalence of genital HPV infection and the HPV vaccination coverage rate among adult men. Results:During the NHANES 2013-2014, a total of 1868 men aged 18 to 59 years were examined. The overall genital HPV infection prevalence was 45.2% (95% CI, 41.3%-49.3%). The infection prevalence with at least 1 high-risk HPV subtype defined by DNA testing was 25.1% (95% CI, 23.0%-27.3%). In vaccine-eligible men, the prevalence of infection with at least 1 HPV strain targeted by the HPV 4-valent vaccine and HPV 9-valent vaccine was 7.1% (95% CI, 5.1%-9.5%) and 15.4% (95% CI, 11.7%-19.6%), respectively. Among vaccine-eligible men, the HPV vaccination coverage was 10.7% (95% CI, 7.8%-14.6%). Conclusions and Relevance:Among men aged 18 to 59 years in the United States, the overall prevalence of genital HPV infection was 45.2% (95% CI, 41.3%-49.3%). The overall genital HPV infection prevalence appears to be widespread among all age groups of men, and the HPV vaccination coverage is low.

journal_name

JAMA Oncol

journal_title

JAMA oncology

authors

Han JJ,Beltran TH,Song JW,Klaric J,Choi YS

doi

10.1001/jamaoncol.2016.6192

subject

Has Abstract

pub_date

2017-06-01 00:00:00

pages

810-816

issue

6

eissn

2374-2437

issn

2374-2445

pii

2598492

journal_volume

3

pub_type

杂志文章
  • Uptake, Results, and Outcomes of Germline Multiple-Gene Sequencing After Diagnosis of Breast Cancer.

    abstract:Importance:Low-cost sequencing of multiple genes is increasingly available for cancer risk assessment. Little is known about uptake or outcomes of multiple-gene sequencing after breast cancer diagnosis in community practice. Objective:To examine the effect of multiple-gene sequencing on the experience and treatment ou...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2018.0644

    authors: Kurian AW,Ward KC,Hamilton AS,Deapen DM,Abrahamse P,Bondarenko I,Li Y,Hawley ST,Morrow M,Jagsi R,Katz SJ

    更新日期:2018-08-01 00:00:00

  • Predictors of Hand-Foot Syndrome and Pyridoxine for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized Clinical Trial.

    abstract:Importance:Hand-foot syndrome (HFS) is a common adverse effect of capecitabine treatment. Objective:To compare the incidence and time to onset of grade 2 or greater HFS in patients receiving pyridoxine vs placebo and to identify biomarkers predictive of HFS. Design, Setting, and Participants:This single-center, rando...

    journal_title:JAMA oncology

    pub_type: 杂志文章,随机对照试验

    doi:10.1001/jamaoncol.2017.1269

    authors: Yap YS,Kwok LL,Syn N,Chay WY,Chia JWK,Tham CK,Wong NS,Lo SK,Dent RA,Tan S,Mok ZY,Koh KX,Toh HC,Koo WH,Loh M,Ng RCH,Choo SP,Soong RCT

    更新日期:2017-11-01 00:00:00

  • Efficacy of Stereotactic Conformal Radiotherapy vs Conventional Radiotherapy on Benign and Low-Grade Brain Tumors: A Randomized Clinical Trial.

    abstract:Importance:Evidence for application of stereotactic and other conformal radiotherapy techniques in treating brain tumors is largely based on data derived from dosimetric, retrospective, or small prospective studies. Therefore, we conducted a randomized clinical trial of stereotactic conformal radiotherapy (SCRT) compar...

    journal_title:JAMA oncology

    pub_type: 杂志文章,随机对照试验

    doi:10.1001/jamaoncol.2017.0997

    authors: Jalali R,Gupta T,Goda JS,Goswami S,Shah N,Dutta D,Krishna U,Deodhar J,Menon P,Kannan S,Sarin R

    更新日期:2017-10-01 00:00:00

  • Prevalence and Spectrum of Germline Cancer Susceptibility Gene Mutations Among Patients With Early-Onset Colorectal Cancer.

    abstract:Importance:Hereditary cancer syndromes infer high cancer risks and require intensive cancer surveillance, yet the prevalence and spectrum of these conditions among unselected patients with early-onset colorectal cancer (CRC) is largely undetermined. Objective:To determine the frequency and spectrum of cancer susceptib...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2016.5194

    authors: Pearlman R,Frankel WL,Swanson B,Zhao W,Yilmaz A,Miller K,Bacher J,Bigley C,Nelsen L,Goodfellow PJ,Goldberg RM,Paskett E,Shields PG,Freudenheim JL,Stanich PP,Lattimer I,Arnold M,Liyanarachchi S,Kalady M,Heald B,Gre

    更新日期:2017-04-01 00:00:00

  • Cardiovascular and Thrombotic Complications of Novel Multiple Myeloma Therapies: A Review.

    abstract:Importance:Multiple myeloma (MM) is the second most common hematological malignant abnormality. The introduction of immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs) has greatly improved the overall survival of patients with MM. Prevention and treatment of cardiovascular and thrombotic issues associated wi...

    journal_title:JAMA oncology

    pub_type: 杂志文章,评审

    doi:10.1001/jamaoncol.2016.3350

    authors: Li W,Garcia D,Cornell RF,Gailani D,Laubach J,Maglio ME,Richardson PG,Moslehi J

    更新日期:2017-07-01 00:00:00

  • Association of Combined Modality Therapy vs Chemotherapy Alone With Overall Survival in Early-Stage Pediatric Hodgkin Lymphoma.

    abstract:Importance:To date, there is no well-defined standard of care for early-stage pediatric Hodgkin lymphoma (HL), which may include chemotherapy alone or combined modality therapy (CMT) with chemotherapy followed by radiotherapy. Although the use of radiotherapy in pediatric HL is decreasing, this strategy remains controv...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2018.5911

    authors: Jhawar SR,Rivera-Núñez Z,Drachtman R,Cole PD,Hoppe BS,Parikh RR

    更新日期:2019-05-01 00:00:00

  • Association Between Germline Mutation in VSIG10L and Familial Barrett Neoplasia.

    abstract:Importance:Esophageal adenocarcinoma and its precursor lesion Barrett esophagus have seen a dramatic increase in incidence over the past 4 decades yet marked genetic heterogeneity of this disease has precluded advances in understanding its pathogenesis and improving treatment. Objective:To identify novel disease susce...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2016.2054

    authors: Fecteau RE,Kong J,Kresak A,Brock W,Song Y,Fujioka H,Elston R,Willis JE,Lynch JP,Markowitz SD,Guda K,Chak A

    更新日期:2016-10-01 00:00:00

  • Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.

    abstract:Importance:Administration of anti-programmed cell death protein 1 (anti-PD-1) is now standard therapy in advanced non-small cell lung cancer (NSCLC). However, immune checkpoint inhibitors, including anti-PD-1, have not been assessed in patients with subclinical disease with advanced NSCLC, and no useful clinical biomar...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2018.5860

    authors: Toi Y,Sugawara S,Sugisaka J,Ono H,Kawashima Y,Aiba T,Kawana S,Saito R,Aso M,Tsurumi K,Suzuki K,Shimizu H,Domeki Y,Terayama K,Nakamura A,Yamanda S,Kimura Y,Honda Y

    更新日期:2019-03-01 00:00:00

  • Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in Patients With Osteosarcoma.

    abstract:Importance:Osteosarcoma, the most common malignant bone tumor in children and adolescents, occurs in a high number of cancer predisposition syndromes that are defined by highly penetrant germline mutations. The germline genetic susceptibility to osteosarcoma outside of familial cancer syndromes remains unclear. Object...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2020.0197

    authors: Mirabello L,Zhu B,Koster R,Karlins E,Dean M,Yeager M,Gianferante M,Spector LG,Morton LM,Karyadi D,Robison LL,Armstrong GT,Bhatia S,Song L,Pankratz N,Pinheiro M,Gastier-Foster JM,Gorlick R,de Toledo SRC,Petrilli AS,

    更新日期:2020-05-01 00:00:00

  • A Magnetic Resonance Imaging-Based Prediction Model for Prostate Biopsy Risk Stratification.

    abstract:Importance:Multiparametric magnetic resonance imaging (MRI) in conjunction with MRI-transrectal ultrasound (TRUS) fusion-guided biopsies have improved the detection of prostate cancer. It is unclear whether MRI itself adds additional value to multivariable prediction models based on clinical parameters. Objective:To d...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2017.5667

    authors: Mehralivand S,Shih JH,Rais-Bahrami S,Oto A,Bednarova S,Nix JW,Thomas JV,Gordetsky JB,Gaur S,Harmon SA,Siddiqui MM,Merino MJ,Parnes HL,Wood BJ,Pinto PA,Choyke PL,Turkbey B

    更新日期:2018-05-01 00:00:00

  • Association of a Bundled-Payment Program With Cost and Outcomes in Full-Cycle Breast Cancer Care.

    abstract:Importance:Value-driven payment system reform is a potential tool for aligning economic incentives with the improvement of quality and efficiency of health care and containment of cost. Such a payment system has not been researched satisfactorily in full-cycle cancer care. Objective:To examine the association of outco...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2016.4549

    authors: Wang CJ,Cheng SH,Wu JY,Lin YP,Kao WH,Lin CL,Chen YJ,Tsai SL,Kao FY,Huang AT

    更新日期:2017-03-01 00:00:00

  • Association of Tumor HER3 Messenger RNA Expression With Panitumumab Efficacy in Advanced Colorectal Cancer.

    abstract:Importance:Epidermal growth factor receptor (EGFR) (HER1) signaling depends on ligand binding and dimerization with itself or other HER receptors. We previously showed in a randomized trial that high EGFR ligand expression is predictive of panitumumab benefit in advanced colorectal cancer. Tumor expression of HER3 may ...

    journal_title:JAMA oncology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1001/jamaoncol.2017.3168

    authors: Seligmann JF,Hatch AJ,Richman SD,Elliott F,Jacobs B,Brown S,Hurwitz H,Barrett JH,Quirke P,Nixon AB,Seymour MT

    更新日期:2018-04-01 00:00:00

  • Combined Epiregulin and Amphiregulin Expression Levels as a Predictive Biomarker for Panitumumab Therapy Benefit or Lack of Benefit in Patients With RAS Wild-Type Advanced Colorectal Cancer.

    abstract:Importance:RAS wild-type (wt) status is necessary but not sufficient for response to anti-epidermal growth factor receptor (EGFR) agents in advanced colorectal cancer (aCRC). RNA expression of EGFR ligands epiregulin (EREG) and amphiregulin (AREG) may correlate with EGFR-targeted therapy efficacy in aCRC, so may repres...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2015.6065

    authors: Seligmann JF,Elliott F,Richman SD,Jacobs B,Hemmings G,Brown S,Barrett JH,Tejpar S,Quirke P,Seymour MT

    更新日期:2016-05-01 00:00:00

  • Single-Fraction Stereotactic vs Conventional Multifraction Radiotherapy for Pain Relief in Patients With Predominantly Nonspine Bone Metastases: A Randomized Phase 2 Trial.

    abstract:Importance:Consensus is lacking as to the optimal radiotherapy dose and fractionation schedule for treating bone metastases. Objective:To assess the relative efficacy of high-dose, single-fraction stereotactic body radiotherapy (SBRT) vs standard multifraction radiotherapy (MFRT) for alleviation of pain in patients wi...

    journal_title:JAMA oncology

    pub_type: 杂志文章,随机对照试验

    doi:10.1001/jamaoncol.2019.0192

    authors: Nguyen QN,Chun SG,Chow E,Komaki R,Liao Z,Zacharia R,Szeto BK,Welsh JW,Hahn SM,Fuller CD,Moon BS,Bird JE,Satcher R,Lin PP,Jeter M,O'Reilly MS,Lewis VO

    更新日期:2019-06-01 00:00:00

  • Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial.

    abstract:Importance:Unresectable intrahepatic cholangiocarcinoma (IHC) carries a poor prognosis, with a median overall survival (OS) of 11 months. Hepatic arterial infusion (HAI) of high-dose chemotherapy may have potential benefit in these patients. Objective:To evaluate clinical outcomes when HAI chemotherapy is combined wit...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2019.3718

    authors: Cercek A,Boerner T,Tan BR,Chou JF,Gönen M,Boucher TM,Hauser HF,Do RKG,Lowery MA,Harding JJ,Varghese AM,Reidy-Lagunes D,Saltz L,Schultz N,Kingham TP,D'Angelica MI,DeMatteo RP,Drebin JA,Allen PJ,Balachandran VP,Lim

    更新日期:2019-10-31 00:00:00

  • Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade.

    abstract:Importance:The anti-programmed cell death protein 1 (PD-1) antibody pembrolizumab is approved by the US Food and Drug Administration for the treatment of microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) solid tumors, but the prevalence of MSI-H/dMMR prostate cancer and the clinical utility of...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2018.5801

    authors: Abida W,Cheng ML,Armenia J,Middha S,Autio KA,Vargas HA,Rathkopf D,Morris MJ,Danila DC,Slovin SF,Carbone E,Barnett ES,Hullings M,Hechtman JF,Zehir A,Shia J,Jonsson P,Stadler ZK,Srinivasan P,Laudone VP,Reuter V,Wo

    更新日期:2019-04-01 00:00:00

  • Risk Adjusting Survival Outcomes in Hospitals That Treat Patients With Cancer Without Information on Cancer Stage.

    abstract:IMPORTANCE:Instituting widespread measurement of outcomes for cancer hospitals using administrative data is difficult owing to lack of cancer-specific information such as disease stage. OBJECTIVE:To evaluate the performance of hospitals that treat patients with cancer using Medicare data for outcome ascertainment and ...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2015.3151

    authors: Pfister DG,Rubin DM,Elkin EB,Neill US,Duck E,Radzyner M,Bach PB

    更新日期:2015-12-01 00:00:00

  • Financial Relationships With Industry Among National Comprehensive Cancer Network Guideline Authors.

    abstract:Importance:Financial conflicts of interest (FCOIs) among authors of clinical practice guidelines have the potential to influence treatment recommendations. Objective:To quantify FCOIs with industry among authors of the National Comprehensive Cancer Network (NCCN) guidelines. Design, Setting, and Participants:We asses...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2016.2710

    authors: Mitchell AP,Basch EM,Dusetzina SB

    更新日期:2016-12-01 00:00:00

  • The Net Chance of a Longer Survival as a Patient-Oriented Measure of Treatment Benefit in Randomized Clinical Trials.

    abstract:IMPORTANCE:Time to events, or survival end points, are common end points in randomized clinical trials. They are usually analyzed under the assumption of proportional hazards, and the treatment effect is reported as a hazard ratio, which is neither an intuitive measure nor a meaningful one if the assumption of proporti...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2015.6359

    authors: Péron J,Roy P,Ozenne B,Roche L,Buyse M

    更新日期:2016-07-01 00:00:00

  • Adjuvant Capecitabine in Combination With Docetaxel, Epirubicin, and Cyclophosphamide for Early Breast Cancer: The Randomized Clinical FinXX Trial.

    abstract:Importance:Capecitabine is not considered a standard agent in the adjuvant treatment of early breast cancer. The results of this study suggest that addition of adjuvant capecitabine to a regimen that contains docetaxel, epirubicin, and cyclophosphamide improves survival outcomes of patients with triple-negative breast ...

    journal_title:JAMA oncology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1001/jamaoncol.2016.6120

    authors: Joensuu H,Kellokumpu-Lehtinen PL,Huovinen R,Jukkola-Vuorinen A,Tanner M,Kokko R,Ahlgren J,Auvinen P,Lahdenperä O,Kosonen S,Villman K,Nyandoto P,Nilsson G,Poikonen-Saksela P,Kataja V,Junnila J,Bono P,Lindman H

    更新日期:2017-06-01 00:00:00

  • Nonadherence to Medications for Chronic Conditions and Nonadherence to Adjuvant Hormonal Therapy in Women With Breast Cancer.

    abstract:Importance:While adjuvant hormonal therapy (HT) reduces mortality for women with nonmetastatic breast cancer, nonadherence to HT is common. Objective:We investigated the association between patterns of prior nonadherence to medications for chronic conditions with HT nonadherence. Design, Setting, and Participants:For...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2016.1291

    authors: Neugut AI,Zhong X,Wright JD,Accordino M,Yang J,Hershman DL

    更新日期:2016-10-01 00:00:00

  • Disparities by Race, Age, and Sex in the Improvement of Survival for Major Cancers: Results From the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program in the United States, 1990 to 2010.

    abstract:IMPORTANCE:Substantial progress has been made in cancer diagnosis and treatment, resulting in a steady improvement in cancer survival. The degree of improvement by age, race, and sex remains unclear. OBJECTIVE:To quantify the degree of survival improvement over time by age, race, and sex in the United States. DESIGN,...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2014.161

    authors: Zeng C,Wen W,Morgans AK,Pao W,Shu XO,Zheng W

    更新日期:2015-04-01 00:00:00

  • Prognostic Survival Associated With Left-Sided vs Right-Sided Colon Cancer: A Systematic Review and Meta-analysis.

    abstract:Importance:Primary tumor location is emerging as an important prognostic factor owing to distinct biological features. However, the side of origin of colon cancer (CC) still does not represent a prognostic parameter when deciding for adjuvant or palliative chemotherapy. Objective:To determine the prognostic role of le...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2016.4227

    authors: Petrelli F,Tomasello G,Borgonovo K,Ghidini M,Turati L,Dallera P,Passalacqua R,Sgroi G,Barni S

    更新日期:2017-02-01 00:00:00

  • Second Primary Malignant Neoplasms and Survival in Adolescent and Young Adult Cancer Survivors.

    abstract:Importance:Although the increased incidence of second primary malignant neoplasms (SPMs) is a well-known late effect after cancer, few studies have compared survival after an SPM to survival of the same cancer occurring as first primary malignant neoplasm (PM) by age. Objective:To assess the survival impact of SPMs in...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2017.0465

    authors: Keegan THM,Bleyer A,Rosenberg AS,Li Q,Goldfarb M

    更新日期:2017-11-01 00:00:00

  • Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcoma: A Nonrandomized Controlled Trial.

    abstract:Importance:Currently, preoperative radiotherapy for all soft-tissue sarcomas is identical at a 50-Gy dose level, which can be associated with morbidity, particularly wound complications. The observed clinical radiosensitivity of the myxoid liposarcoma subtype might offer the possibility to reduce morbidity. Objective:...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2020.5865

    authors: Lansu J,Bovée JVMG,Braam P,van Boven H,Flucke U,Bonenkamp JJ,Miah AB,Zaidi SH,Thway K,Bruland ØS,Baldini EH,Jebsen NL,Scholten AN,van den Ende PLA,Krol ADG,Ubbels JF,van der Hage JA,van Werkhoven E,Klomp HM,van der

    更新日期:2021-01-01 00:00:00

  • Time to Surgery and Breast Cancer Survival in the United States.

    abstract:IMPORTANCE:Time to surgery (TTS) is of concern to patients and clinicians, but controversy surrounds its effect on breast cancer survival. There remains little national data evaluating the association. OBJECTIVE:To investigate the relationship between the time from diagnosis to breast cancer surgery and survival, usin...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2015.4508

    authors: Bleicher RJ,Ruth K,Sigurdson ER,Beck JR,Ross E,Wong YN,Patel SA,Boraas M,Chang EI,Topham NS,Egleston BL

    更新日期:2016-03-01 00:00:00

  • Agent Orange Exposure and Monoclonal Gammopathy of Undetermined Significance: An Operation Ranch Hand Veteran Cohort Study.

    abstract:IMPORTANCE:Multiple myeloma has been classified as exhibiting "limited or suggestive evidence" of an association with exposure to herbicides in Vietnam War veterans. Occupational studies have shown that other pesticides (ie, insecticides, herbicides, fungicides) are associated with excess risk of multiple myeloma and i...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2015.2938

    authors: Landgren O,Shim YK,Michalek J,Costello R,Burton D,Ketchum N,Calvo KR,Caporaso N,Raveche E,Middleton D,Marti G,Vogt RF Jr

    更新日期:2015-11-01 00:00:00

  • Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer: The Canadian Cancer Trials Group CO.26 Study.

    abstract:Importance:Single-agent immune checkpoint inhibition has not shown activities in advanced refractory colorectal cancer (CRC), other than in those patients who are microsatellite-instability high (MSI-H). Objective:To evaluate whether combining programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated pro...

    journal_title:JAMA oncology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1001/jamaoncol.2020.0910

    authors: Chen EX,Jonker DJ,Loree JM,Kennecke HF,Berry SR,Couture F,Ahmad CE,Goffin JR,Kavan P,Harb M,Colwell B,Samimi S,Samson B,Abbas T,Aucoin N,Aubin F,Koski SL,Wei AC,Magoski NM,Tu D,O'Callaghan CJ

    更新日期:2020-06-01 00:00:00

  • Evaluation of the Quality of Adjuvant Endocrine Therapy Delivery for Breast Cancer Care in the United States.

    abstract:Importance:Randomized trials in breast cancer have demonstrated the clinical benefits of adjuvant endocrine therapy (AET) in preventing recurrence and death. The examination of concordance with AET guidelines at a national level as a measure of quality of care is important. Objective:To investigate temporal trends and...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2016.6380

    authors: Daly B,Olopade OI,Hou N,Yao K,Winchester DJ,Huo D

    更新日期:2017-07-01 00:00:00

  • Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.

    abstract:IMPORTANCE:The anti-PD-1 therapeutic antibody, nivolumab, has demonstrated clinical activity in patients with advanced melanoma. The activity of nivolumab in subgroups of patients with tumors which have wild-type BRAF kinase vs patients with tumors having mutant BRAF has not systematically been explored in a large data...

    journal_title:JAMA oncology

    pub_type: 杂志文章,meta分析

    doi:10.1001/jamaoncol.2015.1184

    authors: Larkin J,Lao CD,Urba WJ,McDermott DF,Horak C,Jiang J,Wolchok JD

    更新日期:2015-07-01 00:00:00